Results 151 to 160 of about 16,022 (277)

Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach [PDF]

Elin M. Matsson, Michael Desch, Valerie Nock, Nina Hanke   +3 more
openalex   +1 more source

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 30-32, January 2026.
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Janne T. Backman
wiley   +1 more source

PBPK Models of Two CNS Stimulants, Amphetamine and Methylphenidate, for Clinical Dosing Regimen Optimizations [PDF]

, 2020
Junmei Wang
openalex   +1 more source

Bifenthrin Under Scrutiny: Revisiting Toxicological Evidence Amid Regulatory Gaps

Journal of Applied Toxicology, Volume 46, Issue 1, Page 61-77, January 2026.
ABSTRACT Despite growing health concerns, bifenthrin (BF) remains widely used for controlling agricultural and residential pests. However, different perspectives on its toxicological profile and regulatory framework warrant a revisit and update on BF regulation towards a robust risk‐safety assessment.
Caroline V. L. Moreira, John Ogbu I, Kadja L. C. Monteiro, Thiago M. de Aquino, Edeildo F. da Silva‐Júnior, Alberto S. S. Filho, Hamilton B. Napolitano, Christianah A. Elusiyan, Renê O. do Couto, Elson A. Costa, James O. Fajemiroye   +10 more
wiley   +1 more source

Mode-of-Action Uncertainty for Dual-Mode Carcinogens: A Bounding Approach for Naphthalene-Induced Nasal Tumors in Rats Based on PBPK and 2-Stage Stochastic Cancer Risk Models

, 2007
Kenneth T. Bogen
openalex   +2 more sources

Monte Carlo Simulation in Environmental Risk Assessment--Science, Policy and Legal Issues [PDF]

, 1998
Dr. Poulter notes that agencies should anticipate judicial requirements for justification of Monte Carlo simulations and, meanwhile, should consider, e.g., whether their use will make risk assessment policy choices more opaque or ...
Poulter, Susan R.
core   +1 more source

13 Feasibility of the pragmatic PBPK modelling approach – towards model-informed dosing in paediatric clinical care [PDF]

, 2023
Joyce van der Heijden, Jolien J. M. Freriksen, Marika de Hoop‐Sommen, Rick Greupink, Saskia N. de Wildt   +4 more
openalex   +1 more source

Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry [PDF]

, 2013
Malcolm Rowland
openalex   +1 more source

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
Obesity, MASH and Statins: Insights from a PBPK/PD Zonal Liver Model. ABSTRACT Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction‐associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin ...
William A. Murphy, Noora Sjöstedt, Mailys De Sousa Mendes, Mattie Hartauer, Kim L. R. Brouwer, Sibylle Neuhoff   +5 more
wiley   +1 more source

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin [PDF]

, 2018
Nina Hanke, Sebastian Frechen, Daniel Moj, Hannah Britz, Thomas Eißing, Thomas Wendl, Thorsten Lehr   +6 more
openalex   +1 more source